BDTX

Black Diamond TherapeuticsB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$2.60

Analysis reference price unavailable

Analysis 2026-10-14 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$1.85

Analysis reference price unavailable

Analysis 2026-10-14 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$0.90

Analysis reference price unavailable

Analysis 2026-10-14 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-14

AI commentary

The company-confirmed clinical update is constructive, but no later clinical or FDA outcome was verified. A September Zacks follow-up reported a $0.17 Q2 loss versus its $0.18 consensus estimate and downward subsequent estimate revisions; those are secondary-source observations, not evidence of pivotal success. Zacks follow-up Current analyst revisions, options skew, short interest, employee sentiment and social coverage are unavailable; the zero sentiment-field values denote missing data, not neutral readings.

RankAlpha Sentiment Codex - 2026-10-14

Open full AI memo

Evidence flagged

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-12-31eventQ4 silevertinib NSCLC update and FDA feedbackHigh impact

Black Diamond expects a Q4 2026 Phase 2 update and FDA feedback on a potential pivotal path in frontline non-classical EGFR-mutant NSCLC. Its prior 43-patient dataset showed 60% objective response and 86% CNS objective response; durability and the regulatory path remain the key tests [#SEC-8K-2026-08-05]. SEC earnings exhibit

2026-12-31eventGBM trial randomized-phase initiationHigh impact

The silevertinib-plus-temozolomide Phase 2 glioblastoma study was enrolling its safety lead-in; management targeted Q4 2026 initiation of the randomized portion. This is an execution milestone, not a clinical readout [#SEC-8K-2026-08-05]. SEC earnings exhibit

2028-06-30catalystRunway supports clinical developmentMedium impact

The company reported $110.5 million in cash, equivalents and investments at June 30, 2026 and expected funding into the second half of 2028. Future trial spending could change that estimate [#SEC-8K-2026-08-05]. SEC earnings exhibit

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-14 • Updated nightlySource: Internal modelMethodology